OakChart

Oncolytics Biotech Inc

ONCYHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 11:15 AM ET

0.3935+0.0117 (3.06%)
2026-11-11 17:16 CET
Market cap
38.32 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-30.07 USD m
Free cash flow, TTM
-26.53 USD m
EPS diluted, TTM
-0.27
P/E
-
Compare

Price

ONCY against its 20, 50 and 200-day averages
2050200miss
0.400.600.801.001.204.1M8.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ONCYclose 0.3920-day 0.4550-day 0.60200-day 0.840.39

69.7% under the 52-week high of 1.30 on 22 Jan 2026. 52-week low 0.37 on 11 Nov 2026. Last 15 sessions, 41.3% high to low

Profile

ONCY
52-week range, 1% of the way up
0.381.30

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Employees29
IPOOct 05, 2001
Beta1.25
ATR, 14d0.04
Rel volume1.15
Short float8.78%
Insider own1.55%
Inst own11.93%

Snapshot

6 groups

Valuation

Index-
Market Cap50.17M
Enterprise Value46.50M
Income-30.07M
Sales0.00M
Book/sh-0.05
Cash/sh0.03
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees29
IPOOct 05, 2001

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C12.18
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio1.35
Current Ratio1.35
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.27
EPS next Y-0.20
EPS next Q-0.05
EPS this Y-18.48%
EPS next Y21.72%
EPS next 5Y4.29%
EPS past 3/5Y3.00% 6.32%
Sales past 3/5Y- -
EPS Y/Y TTM2.05%
Sales Y/Y TTM-
EPS Q/Q-35.86%
Sales Q/Q-
EarningsAug 12 BMO
EPS/Sales Surpr.-46.79% -

Ownership

Insider Own1.55%
Insider Trans0.00%
Inst Own11.93%
Inst Trans0.09%
ROA-277.89%
ROE-11838.99%
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-13.24%
SMA50-34.11%
SMA200-52.88%
Trades-

Technical

Shs Outstand124.64M
Shs Float98.81M
Short Float8.78%
Short Ratio8.06
Short Interest8.68M
52W High1.30 -69.73%
52W Low0.38 3.15%
Volatility13.74% 10.41%
ATR (14)0.04
RSI (14)31.88
Beta1.25
Rel Volume1.15
Avg Volume1.08M
Volume377,576

Performance

Perf Week-7.37%
Perf Month-19.69%
Perf Quarter-50.81%
Perf Half Y-54.82%
Perf YTD-54.98%
Perf Year-63.56%
Perf 3Y-72.86%
Perf 5Y-80.42%
Perf 10Y-79.29%
Recom1.40
Target Price4.46
Prev Close0.38
Price0.39
Change %3.06%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Aug 13, 2025InitiatedLLake StreetBuy$7+1,678.9%
Oct 06, 2022InitiatedMMaxim GroupBuy$3+662.4%
Feb 17, 2021InitiatedHH.C. WainwrightBuy$15+3,711.9%

Peers

Mkt cap
TickerCompanyMkt cap
GNLXGenelux Corp89.36M
CADLCandel Therapeutics Inc725.40M
CRDFCardiff Oncology Inc60.61M
REPLReplimune Group Inc2.15B
AGENAgenus Inc324.09M
CGONCg Oncology Inc6.64B
ELTXElicio Therapeutics Inc43.59M
CLDICalidi Biotherapeutics Inc2.53M
PDSBPDS Biotechnology Corp106.58M
RVMDRevolution Medicines Inc40.01B

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Parsons James T.DirectorMar 11 '26Buy1.0310,00010,30041,849Mar 13 08:00 AM
Kelly JaredChief Executive OfficerMar 12 '26Buy0.965,0504,848114,050Mar 13 08:00 AM
Kelly JaredChief Executive OfficerFeb 12 '26Buy0.8429,50024,839109,000Feb 13 07:00 AM
Kelly JaredChief Executive OfficerFeb 11 '26Buy0.845,6004,68279,500Feb 13 07:00 AM
Look KirkChief Financial OfficerFeb 12 '26Buy0.8412,00010,104287,515Feb 13 07:00 AM
Pisano WayneDirectorFeb 12 '26Buy0.8430,00025,338492,414Feb 13 07:00 AM
Heineman Thomas CharlesChief Medical OfficerFeb 12 '26Buy0.8312,13210,033282,818Feb 13 07:00 AM
Brown Deborah MargaretDirectorFeb 12 '26Buy0.8525,00021,240109,851Feb 13 07:00 AM
Hagerman AllisonVP, Product DevelopmentFeb 12 '26Buy0.8310,0008,298115,059Feb 13 07:00 AM
Seizinger Bernd R.DirectorFeb 11 '26Buy0.8360,00049,590526,991Feb 13 07:00 AM
Seizinger Bernd R.DirectorFeb 12 '26Buy0.8540,00033,864566,991Feb 13 07:00 AM
Aromando AndrewChief Business OfficerFeb 11 '26Buy0.8629,60025,41855,100Feb 13 07:00 AM
Andrews Patricia SDirectorFeb 12 '26Buy0.8635,40030,29278,128Feb 13 07:00 AM
Seizinger Bernd R.DirectorJan 16 '26Buy1.04100,000103,770466,991Jan 20 04:30 PM

Held by

AUM
TickerCompanyAUM
QQQSInvesco NASDAQ Future Gen 200 ETFAUM: 20.53M

News

latest 14 of 206
  • Pelareorep Induces Coordinated Antiviral Immune Responses and Enhanced Antitumor Immunity in Multiple Myeloma Patients (GlobeNewswire) -7.21%
  • Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers (GlobeNewswire) +8.92%
  • Oncolytics Biotech Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers (GlobeNewswire)
  • Oncolytics Biotech to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer (GlobeNewswire)
  • Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment (GlobeNewswire) +9.84%
  • Loading…
  • Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda (PR Newswire)
  • Oncolytics Biotech Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update (GlobeNewswire) -15.03%
  • Oncolytics Biotech Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy (GlobeNewswire)
  • Oncolytics Biotech Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study (GlobeNewswire)
  • KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 (PR Newswire)
  • Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer (GlobeNewswire)
  • Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer (GlobeNewswire)
  • Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-12-0.080-0.055-0.0680.000.005
2026Q12026-05-14-0.080-0.044-0.0820.000.005
2025Q42026-03-30-0.007-0.064-0.0140.000.005
2025Q32025-11-13-0.100-0.061-0.0980.000.005
2025Q22025-08-08-0.051-0.073-0.0580.000.004
2025Q12025-05-14-0.057-0.070-0.0560.000.003
2024Q42025-03-07-0.070-0.087-0.0740.000.004
2024Q32024-11-12-0.086-0.074-0.0910.000.005
2024Q22024-08-01-0.072-0.075-0.0700.000.006
2024Q12024-05-09-0.066-0.083-0.0680.000.005
2023Q42024-03-07-0.037-0.108-0.0390.000.006
2023Q32023-11-03-0.102-0.079-0.1060.000.006
2023Q22023-08-14-0.089-0.088-0.0860.000.004
2023Q12023-05-05-0.074-0.094-0.0760.000.004
2022Q42023-03-03-0.103-0.072-0.1060.000.004
2022Q32022-11-07-0.059-0.084-0.0580.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.930-0.676-1.1280.000.00
2020FY-0.441-0.399-0.4160.000.00
2021FY-0.384-0.359-0.3920.000.00
2022FY-0.316-0.296-0.3290.000.00
2023FY-0.305-0.370-0.3040.000.00
2024FY-0.287-0.290-0.2980.000.00
2025FY-0.215-0.266-0.2570.000.00
2026FY--0.251--0.00
2027FY--0.196--0.00
2028FY--0.185--0.00
2029FY--0.184--0.00
2030FY--0.100--132.05

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-183000.000.000.00
2026Q3S2026-08-124000.000.000.00
2026Q3S2026-06-104000.000.000.00
2026Q3S2026-05-153000.000.000.00
2026Q3S2026-04-073000.000.000.00
2026Q3S2026-04-062000.000.000.00
2026Q3S2026-03-311000.000.000.00
2026Q3S2025-11-182000.000.000.00
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00

Estimate history

EPS, annual-0.878-0.821-1.128-0.416-0.392-0.329-0.304-0.298-0.3-0.2726
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.07-0.091-0.074-0.056-0.058-0.098-0.014-0.082-0.079
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual14.92717.432.19846.16755.04461.32874.42480.02108.021124.638
Period201720182019202020212022202320242025MRQ
Shares, quarterly76.85777.07480.0286.42297.408103.636108.021116.128124.638
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.110.070.090.300.300.360.330.370.07
Gross Profit0.00-0.07-0.09-0.30-0.30-0.36-0.33-0.37-0.07
Selling, General and Administrative Excl. Other30.2928.6625.4624.7420.3820.5618.6514.8113.20
Research and Development-13.3115.4413.1211.8510.319.658.157.74
Other Operating Expense0.000.000.000.000.000.000.000.000.05
Operating Income-30.40-28.73-25.54-25.04-20.68-20.93-18.98-15.18-13.33
Interest Expense--------0.00
Unusual Expense-0.080.24-1.17-3.920.02-0.01-2.609.68-
Net Income Before Taxes-29.90-28.68-22.70-20.49-19.01-20.94-16.78-24.96-12.72
Income Taxes0.170.080.100.070.060.040.000.000.42
Consolidated Net Income-30.07-28.76-22.79-20.56-19.08-20.98-16.78-24.96-13.14
Net Income From Continuing Operations-30.07-28.76-22.79-20.56-19.08-20.98-16.78-24.96-13.14
Net Income-30.07-28.76-22.79-20.56-19.08-20.98-16.78-24.96-13.14
EPS (Recurring)-0.25-0.30-0.31-0.34-0.33-0.39-0.46-0.82-0.82
EPS (Basic, Before Extraordinaries)-0.27-0.30-0.30-0.30-0.33-0.39-0.42-1.13-0.82
EPS (Diluted)-0.27-0.30-0.30-0.30-0.33-0.39-0.42-1.13-0.82
EBITDA-30.34-28.66-25.45-24.74-20.38-20.56-18.65-14.81-13.25
Non-Operating Income (Expense)0.420.281.670.631.68-0.03-0.40-0.100.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.284.731.431.301.552.241.911.111.09
Shares Outstanding124.64108.0280.0274.4261.3355.0446.1732.2017.40
Market Capitalization38.3238.3270.4399.0996.2276.49103.05125.4630.88

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.020.000.080.020.020.070.08
Gross Profit-0.01-0.020.00-0.08-0.02-0.02-0.07-0.08
Selling, General and Administrative Excl. Other9.369.272.189.484.635.005.967.18
Research and Development4.264.55-5.081.922.803.264.98
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.38-9.28-2.18-9.56-4.65-5.02-6.03-7.26
Interest Expense----0.000.00--
Unusual Expense0.000.00-0.770.690.47-0.230.07-0.17
Net Income Before Taxes-9.34-9.24-1.26-10.06-5.22-4.71-5.72-6.99
Income Taxes0.100.000.25-0.180.060.000.020.01
Consolidated Net Income-9.44-9.24-1.51-9.88-5.28-4.71-5.73-7.00
Net Income From Continuing Operations-9.44-9.24-1.51-9.88-5.28-4.71-5.73-7.00
Net Income-9.44-9.24-1.51-9.88-5.28-4.71-5.73-7.00
EPS (Recurring)-0.08-0.08-0.02-0.09-0.05-0.06-0.07-0.09
EPS (Basic, Before Extraordinaries)-0.08-0.08-0.01-0.10-0.06-0.06-0.07-0.09
EPS (Diluted)-0.08-0.08-0.01-0.10-0.06-0.06-0.07-0.09
EBITDA-9.36-9.27-2.38-9.48-4.63-5.00-5.96-7.18
Non-Operating Income (Expense)0.040.040.150.19-0.100.080.380.10
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.933.030.431.890.270.850.620.23
Shares Outstanding124.64116.13108.02103.6497.4186.4280.0277.07
Market Capitalization38.3285.1987.72140.5168.6647.5370.4367.05

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.2011.0826.4823.7232.6724.5110.9110.039.45
Short Term Receivables0.570.050.010.380.690.071.600.043.83
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.071.312.462.232.201.912.090.510.94
Total Current Assets6.8412.4428.9526.3435.5526.4814.6010.5814.22
Net Property, Plant & Equipment0.740.980.490.480.770.480.560.300.27
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.000.740.000.000.000.000.00
Total Assets7.5813.4229.4427.5536.3226.9615.1610.8814.49
Short Term Debt Incl. Current Port. of LT Debt0.190.200.100.160.230.200.260.000.00
Accounts Payable0.000.000.000.000.000.000.000.000.00
Other Current Liabilities5.914.683.112.751.901.939.662.064.17
Total Current Liabilities6.104.883.212.912.132.139.922.064.17
Long Term Debt0.370.560.220.120.290.120.130.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities4.914.685.104.975.335.285.194.293.70
Total Liabilities11.3810.128.547.997.747.5315.246.357.87
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-3.803.3020.9019.5628.5819.43-0.084.546.61
Total Shareholders Equity-3.803.3020.9019.5628.5819.43-0.084.546.61
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-3.803.3020.9019.5628.5819.43-0.084.546.61
Total Liabilities & Stockholders Equity7.5813.4229.4427.5536.3226.9615.1610.8814.49
Book Value Per Share-0.040.040.280.320.520.42-0.000.260.44
Tangible Book Value Per Share-0.040.040.280.320.520.42-0.000.260.44
Full-Time Employees29282729262523--
Price to Book Ratio-7.7210.514.624.632.685.66-1,844.966.948.28
Return on Assets-266.06-106.36-72.15-59.73-66.31-79.67-191.70-103.62-94.40
Return on Equity-15,930.26-188.37-101.63-79.26-87.41-173.46-1,121.20-235.83-165.01
Return on Invested Capital--590.67-97.34-96.96-72.69-85.83-55,300.81-289.78-181.98
Quick Ratio1.122.559.019.0516.6912.451.475.133.41
Current Ratio1.122.559.019.0516.6912.451.475.133.41

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-37.25-28.76-22.79-20.56-19.08-20.98-16.78-24.96-13.14
Depreciation0.060.070.090.300.300.360.330.370.07
Other Funds (Non Cash)10.707.400.30-2.120.543.45-0.1610.950.86
Funds from Operations-26.49-21.29-22.41-22.39-18.24-17.17-16.61-13.65-12.21
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.021.182.521.310.30-0.720.16-1.353.01
Cash from Operating Activities-26.52-20.11-19.88-21.08-17.94-17.89-16.45-15.00-9.20
Capital Expenditures-0.01-0.01-0.17-0.01-0.04-0.23-0.02-0.01-0.08
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.0014.99-15.630.000.000.000.00
Purchase of Investments0.000.000.000.00-15.630.000.000.000.00
Sale Or Maturity of Investments0.000.000.0014.990.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.01-0.01-0.1714.98-15.67-0.23-0.02-0.01-0.08
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock20.0714.155.0324.019.6726.6330.0016.1810.26
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock20.0714.155.0324.019.6726.6330.0016.1810.26
Proceedsfrom Stock Options20.0714.154.9823.439.6626.2528.5513.5610.16
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.03-0.030.000.000.000.000.000.000.00
Other Financing Activities Uses-0.03-0.030.000.000.000.000.000.000.00
Cash from Financing Activities20.0414.125.0323.709.3826.3329.6515.8410.26
Exchange Rate Effect-0.120.12-0.29-0.391.50-0.20-0.45-0.490.46
Net Change in Cash-6.61-5.88-15.3217.22-22.738.0112.730.341.44
Free Cash Flow-26.53-20.12-20.06-21.08-17.98-18.12-16.47-15.01-9.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.125.495.208.8710.7210.64
Short Term Receivables1.210.960.570.040.050.06
Inventories0.000.000.000.000.000.00
Other Current Assets1.741.031.071.512.331.30
Total Current Assets7.077.496.8410.4213.1012.01
Net Property, Plant & Equipment0.600.670.740.800.870.92
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets7.678.167.5811.2213.9712.93
Short Term Debt Incl. Current Port. of LT Debt0.140.170.190.210.220.21
Accounts Payable3.400.000.000.000.980.54
Other Current Liabilities1.685.265.916.043.693.27
Total Current Liabilities5.225.426.106.254.894.02
Long Term Debt0.310.340.370.410.450.51
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities8.307.534.914.834.934.68
Total Liabilities13.8413.2911.3811.4910.279.21
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-6.17-5.13-3.80-0.273.703.73
Total Shareholders Equity-6.17-5.13-3.80-0.273.703.73
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-6.17-5.13-3.80-0.273.703.73
Total Liabilities & Stockholders Equity7.678.167.5811.2213.9712.93
Book Value Per Share-0.05-0.04-0.04-0.000.040.04
Tangible Book Value Per Share-0.05-0.04-0.04-0.000.040.04
Full-Time Employees--29---
Price to Book Ratio-7.72-33.081,092.5030.5614.8110.58
Return on Assets-277.89-245.63-197.73-175.45-121.46-117.81
Return on Equity---11,838.99-795.96-266.00-219.77
Return on Invested Capital----7,157.97-127.22-111.34
Quick Ratio1.351.381.121.672.682.99
Current Ratio1.351.381.121.672.682.99

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-9.36-9.24-8.65-10.01-5.45-4.71
Depreciation0.010.02-0.200.240.020.02
Other Funds (Non Cash)2.503.122.053.031.620.71
Funds from Operations-6.84-6.11-6.80-6.74-3.81-3.98
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.22-1.180.541.84-0.45-0.75
Cash from Operating Activities-8.07-7.29-6.26-4.90-4.26-4.73
Capital Expenditures0.00-0.01-0.00-0.00-0.00-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.00-0.01-0.00-0.00-0.00-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock6.707.615.020.734.244.18
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock6.707.615.020.734.244.18
Proceedsfrom Stock Options6.707.615.020.734.244.18
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-2.412.380.000.00
Other Financing Activities Uses0.000.00-0.030.000.000.00
Cash from Financing Activities6.707.612.613.124.244.18
Exchange Rate Effect-0.01-0.020.01-0.090.090.12
Net Change in Cash-1.370.29-3.65-1.880.07-0.43
Free Cash Flow-8.07-7.30-6.26-4.90-4.26-4.73

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.78%8.7M98.8M1.03M
2026-10-159.13%9.0M98.8M1.09M
2026-09-307.46%7.4M98.8M1.11M
2026-09-158.75%8.6M98.8M1.12M
2026-08-317.90%7.8M98.8M1.25M
2026-08-148.59%8.5M98.5M1.35M
2026-07-318.35%8.2M98.5M1.40M
2026-07-158.07%7.9M98.5M1.45M
2026-06-306.71%6.6M98.5M1.31M
2026-06-157.23%7.1M98.5M1.22M
2026-05-297.01%6.9M98.5M1.06M
2026-05-156.97%6.9M98.5M1.12M
2026-04-307.40%7.3M98.3M1.35M
2026-04-156.52%6.4M98.3M1.41M
2026-03-316.30%6.2M98.1M1.35M
2026-03-136.71%6.6M98.1M1.33M
2026-02-276.78%6.7M98.1M1.27M
2026-02-137.35%7.2M98.1M1.14M
2026-01-303.89%3.8M98.5M899.98K
2026-01-153.81%3.8M98.5M753.61K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-09SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-278-KCurrent report2026-10-27SEC
2026-10-208-KCurrent report2026-10-20SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-138-KCurrent report2026-10-12SEC
2026-10-06DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-06DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342025-12-31SEC
2026-09-298-KCurrent report2026-09-29SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-108-KCurrent report2026-09-10SEC
2026-08-188-KCurrent report2026-08-18SEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-248-KCurrent report2026-07-20SEC
2026-07-208-KCurrent report2026-07-20SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-07-088-KCurrent report2026-07-06SEC
2026-06-168-KCurrent report2026-06-16SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-033Initial statement of beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC
2026-06-033Initial statement of beneficial ownership of securities2026-06-01SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-0315.15K200
2026-02243.70K1100
2026-01103.77K100
2025-120000
2025-110000

Institutional holders

Manager% owned
MARSHALL WACE, LLP0.74%
XTX Topco Ltd0.26%
SEEDS INVESTOR LLC0.26%
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC0.20%
Connective Capital Management, LLC0.19%
GOLDMAN SACHS GROUP INC0.17%
Larson Financial Group LLC0.17%
TOCQUEVILLE ASSET MANAGEMENT L.P.0.15%
Everhart Financial Group, Inc.0.14%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.13%

Funds

Fund% owned
Invesco NASDAQ Future Gen 200 ETF0.11%
Fidelity Nasdaq Composite Index Fund0.07%
Victory Extended Market Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. ONCY. Cached 15 minutes.